FDA to reconsider treatment for rare cancer after surprise rejection

Secret drug pricing deals, a virtual AI cancer clinic, and other biotech news from The Readout FDA global health virology Newsletters Log In My Account Subscribe Now My Account Settings Complete your personal information for a more tailored experience Billing Log Out A decade of reporting from the frontiers of health and medicine Newsletters Log In My Account Subscribe Now Biotech Pharma Public Health Health Tech Policy Science First Opinion STAT+ STAT Events Search Log In Try STAT+ My Account Home Newsletter The Readout FDA to reconsider treatment for rare cancer after surprise rejection Secret drug pricing deals, a virtual…

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

The Trump administration is touting massive projected savings from its still-secret drug pricing deals, though outside experts say there’s little way to independently verify the math.

Also, FDA leadership is facing fresh accusations of political interference in drug reviews, AI oncology startups are trying to make cancer care virtual, and scientists are opening up an entirely new frontier of biology hidden inside the “dark proteome.”

Continue to STAT+ to read the full story…